Table 2 Outcome and final diagnosis of PTCNB/TBLB in 155 patients
Lung lesion | TBLB outcome | PTCNB outcome | Final diagnosis |
|---|---|---|---|
Malignant | 28 (28/155; 18.06%) | 34 (34/155; 21.94%) | 47 (47/155; 30.32%) |
Lung adenocarcinoma | 15 (15/155; 9.68%) | 26 (26/155; 16.77%) | 29 (29/155; 18.71%) |
Lung squamous carcinoma | 8 (8/155; 5.16%) | 5 (5/155; 3.23%) | 12 (12/155; 7.74%) |
Sarcomatoid carcinoma | 1 (1/155; 0.65%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Neuroendocrine carcinoma | 3 (3/155; 1.94%) | 2 (2/155; 1.29%) | 3 (3/155; 1.94%) |
Adenosquamous carcinoma | 1 (1/155; 0.65%) | 1 (1/155; 0.65%) | 1 (1/155; 0.65%) |
Lymphoma | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Specific-benign | 11 (11/155; 7.10%) | 44 (44/155; 28.39%) | 68 (68/155; 43.87%) |
Tuberculosis | 7 (7/155; 4.52%) | 14 (14/155; 9.03%) | 15 (15/155; 9.68%) |
Organized pneumonia | 1 (1/155; 0.65%) | 24 (24/155; 15.48%) | 26 (26/155; 16.77%) |
Sarcoidosis | 2 (2/155; 1.29%) | 2 (2/155; 1.29%) | 3 (3/155; 1.94%) |
Abscess | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) | 13 (13/155; 8.39%) |
Cryptococcus | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) | 1 (1/155; 0.65%) |
Pneumocystis carinii pneumonia | 1 (1/155; 0.65%) | 1 (1/155; 0.65%) | 1 (1/155; 0.65%) |
Actinomycetes | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Non-tuberculous mycobacteria | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Benign tumor | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) | 2 (2/155; 1.29%) |
Vasculitis | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 3 (3/155; 1.94%) |
Sicca syndrome related disease | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Non-tuberculous mycobacteria | 0 (0/155; 0.00%) | 0 (0/155; 0.00%) | 1 (1/155; 0.65%) |
Non-specific benign | 113 (113/155; 72.90%) | 76 (76/155; 49.03%) | 40 (40/155; 25.81%) |
Non-diagnostic | 3 (3/155; 1.94%) | 1 (1/155; 0.65%) | 0 (0/155; 0.00%) |